Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

DecisionHealth partners with innoviHealth to offer an HCC calculator…


DecisionHealth, an HCPro brand, is proud to announce the launch of a new add-on option for SelectCoder: a Hierarchical Condition Category (HCC) calculator. The HCC calculator is used to calculate…

(PRWeb January 18, 2023)

Read the full story at https://www.prweb.com/releases/decisionhealth_partners_with_innovihealth_to_offer_an_hcc_calculator_add_on_to_selectcoder_the_premier_online_coding_resource/prweb18940709.htm

CellMax Life Announces Positive Results From Prospective Multisite Study of Novel Blood Test to Detect Colorectal Cancer and Pre-Cancer


The results from this study are incredibly promising, showing significant potential for this test for colorectal non-invasive cancer screening, thereby increasing our ability to prevent more cancers – Shai Friedland, MD, Stanford Medicine

CellMax Life, a molecular diagnostics company with a proprietary colorectal cancer screening blood test, today announced positive results from a multisite U.S. study that showed that its FirstSightTM blood test is highly accurate in detecting colorectal cancer, as well as advanced adenomas.

The data from this prospective study showed that CellMax’s FirstSight blood test demonstrated 92% sensitivity for colorectal cancer and 55% sensitivity for advanced adenomas at 91% specificity. This data aligns well with the 16-year follow-up of the National Polyp Study, in which investigators made the case that advanced adenomas should be a primary target of colorectal cancer screening.

“Simply put, colorectal cancer is preventable; many cases that occur could have been avoided had the right screening tests been performed in a timely manner,” said Douglas K. Rex, MD, Distinguished Professor Emeritus of Medicine at Indiana University School of Medicine, Former President of the American Society for Gastrointestinal Endoscopy and Former Chair of the U.S. Multi-Society (ACG, ASGE, AGA) Task Force on Colorectal Cancer. “In order to significantly reduce the incidence of colorectal cancer, an effective and easy screening test is critical. This is why I am very enthusiastic about this data on CellMax’s FirstSight. The study demonstrated numerically better detection of advanced adenomas than the best performing commercially available fecal tests, as well as other blood tests that are currently under development and have publicly disclosed their performance.”

The study was designed to reflect an asymptomatic average-risk U.S. screening population and consisted of 1038 samples collected from patients between the ages of 45-80 across 18 geographically dispersed sites. Of these 1038 samples, 954 were asymptomatic, average-risk screening patients without age enrichment, including 11 patients with colorectal cancer (2 stage I, 3 stage II, 6 stage III) and 93 patients with advanced adenomas. Additionally, 84 were case-control diseased patients with 65 known cases of colorectal cancer (9 stage I, 20 stage II, 22 stage III, 6 stage IV, 8 unstaged), and 19 known cases of advanced adenomas prior to resection to increase statistical power. All negative samples were collected from the average- risk screening cohort, and there were no negative case-control samples.

These results demonstrate best-in-class performance for detection of advanced neoplasia (colorectal cancer and advanced adenomas). CellMax’s FirstSight is the first blood test that is superior to stool tests in detecting advanced adenomas and colorectal cancer.

“There is a significant clinical unmet need when it comes to detecting colorectal cancer and pre-cancer,” said Shai Friedland, MD, lead principal investigator on the study and gastroenterologist at Stanford Medicine. “The results from this study are incredibly promising, showing significant potential for this test for colorectal non-invasive cancer screening, thereby increasing our ability to prevent more cancers.”

The multi-modal FirstSight blood test differs significantly from other first-generation ctDNA blood tests. It is able to detect advanced adenomas by combining signatures, not just from ctDNA but also from methylation along with rare epithelial cells shed from adenomas using the company’s proprietary circulating epithelial cells technology. These are all combined into a proprietary algorithm that also captures interaction between these selective biomarkers.

“There are too many unnecessary deaths from colorectal cancer,” said Atul Sharan, co-founder and CEO of CellMax Life. “Our mission with FirstSight is to find precancerous adenomas that have a high likelihood of progression to cancer and detect them before they develop into cancer. To that end, the study was designed and analyzed such that there can be high confidence that the results will be reproduced in a larger premarket approval study.”

Based on clinical data showing FirstSight’s ability to detect both colorectal cancer and advanced adenomas with high sensitivity, CellMax received Breakthrough Device Designation from the U.S. Food and Drug Administration in Q3 2021.

This data will be presented at ASCO Gastrointestinal Cancers Symposium, taking place on January 19-21, 2023. Details for the poster presentation include:

Poster Session C: Cancers of the Colon, Rectum, and Anus

January 21, 2023, at 6:30 AM PST

Location: Level 1, West Hall

Poster Abstract #75, Poster Board D12

Presented by Lead PI Dr. Shai Friedland of Stanford University Medical Center Gastroenterology and Hepatology

CellMax plans to begin a premarket approval study, with an intermediate endpoint for advanced adenoma due to their higher prevalence relative to cancer and an end-of-study endpoint of advanced adenoma plus colorectal cancer (advanced neoplasia) test that provides increased level of evidence to cancer detection due to lower prevalence. If approved, FirstSight blood test will help increase routine screening compliance for patients who are reluctant to undergo a colonoscopy or stool testing and may help prevent colorectal cancer by detecting the disease at the advanced adenoma stage.

About CellMax Life

CellMax Life is a diagnostics company focused on cancer screening with proprietary technology for detecting precancerous and cancer cells and genomic aberrations in a single blood sample. CellMax Life is headquartered in Sunnyvale, California, and has an accredited laboratory at this location. For more information, visit http://www.cellmaxlife.com.

Media Contact:

Leonard Fontes III

Cellmaxlife@antennagroup.com

(201) 874-6317

Share article on social media or email:

The Top 25 Healthcare Technology Leaders of Virginia for 2023


The Healthcare Technology Report is pleased to announce The Top 25 Healthcare Technology Leaders of Virginia for 2023. While other East Coast hot spots like New York, Boston, and DC may get more attention when it comes to their healthcare technology markets, Virginia is by no means a slouch. The state is home to a number of incredibly innovative healthtech companies across a range of specialties, from pharmaceuticals to biologics, diagnostics, and medical devices, among many others. The leaders on this year’s list earned their spots thanks to their dedication to revolutionizing the industry within their specialties, delivering technologies that have the ability to transform the lives of patients and the work of clinicians.

Some of the distinguished leaders on this year’s list include Ashley Pleasants, Vice President Project Management at Elligo Health Research, whose services are dramatically accelerating the development of new pharmaceutical, biotechnology, and medical device and diagnostic products. Meanwhile, Chief Scientist David Gerdt’s CareTaker Medical has developed VitalStream, the world’s most innovative, FDA-cleared wearable vital signs monitor and early warning device. And Co-Founder and CEO Rust Felix’s Slope has developed the online eClinical Supply Chain Management (eCSCM) platform, which reduces clinical trial risks, reigns in costs, and improves the productivity of clinical trial collaborators.

This year’s awardees lead from a variety of positions, from CEO to CFO, VP, COO, and CTO. What they have in common is their demonstrated commitment to innovating in the healthcare technology space, prioritizing patient well-being in the Virginia area and around the world. Please join us in celebrating The Top 25 Healthcare Technology Leaders of Virginia for 2023.

Chris Senanayake (TCG GreenChem, Inc.), Douglas Boothe (Akorn), Keith Sullivan (Neuronetics), Ashley Pleasants (Elligo Health Research), Gregory Forton (ATCC), David Gerdt (CareTaker Medical), Rust Felix (Slope), Marjorie Zettler (Regor Pharmaceuticals Inc.), Brian Mills (Vista Clinical Diagnostics), April Hall (Biomere), Paul Bishop (Atlantic Research Group), Nathaniel Wuertz (Orthosnap), Hunter Walker (Atlantic Research Group), Ronald Gunn (Kaléo), Mike Cariola (Bode Technology), Libby Lynes (BioTel Heart), Jeff Conroy (Embody), Micah Cost (Pharmacy Quality Alliance), Jennifer Brearey (AdvaMed), Eric Edwards (Phlow Corporation), Kristina Peterman (ATCC), Juan Piacquadio (Phlow Corporation), David Voight (Acceleration Point), Kenneth Guito (Biologics Consulting), Kevin Breheny (AccuTec Blades).

The full article can be read at https://thehealthcaretechnologyreport.com/

About The Healthcare Technology Report

The Healthcare Technology Report provides market research and insights, business news, investment activity updates, and important corporate developments related to the healthcare technology sector. Based in New York City, the firm is run by a seasoned team of editors, writers, and media professionals highly knowledgeable on healthcare technology and the various companies, executives, and investors that make up the sector.

Share article on social media or email:

Cornerstone Prosthetics & Orthotics Provides Ukrainian Amputees with Prosthetic Care


Cornerstone patient using running blade.

Cornerstone Patient using a running blade for the first time.

Mike Smith, Partner and Practioner of Cornerstone Prosthetic & Orthotics, explains, “We look forward to continuing our collaboration with the UKRHelp Foundation on a meaningful and humanitarian mission to help Ukrainian amputees have access to prosthetic care.”

Through this partnership, UKRHelp Foundation and Cornerstone Prosthetics and Orthotics aim to bring necessary medical care to those individuals affected by the current war in Ukraine by providing prosthetics to amputees and training Ukrainians to manage long-term care for those with amputations. This partnership is critical to providing better prosthetics access to Ukraine. The ongoing conflict significantly impacts individuals’ access to basic medical and mental health support, specifically for young adults with amputations.

The UKRHelp Foundation is a non-profit organization based in Washington State that provides medical care and prosthetics to those affected by war. They are driven by a single goal – ensuring a safe future for every child, young adult, and adult living through the war in Ukraine. The Foundation works with local organizations, such as hospitals and clinics, to provide medical care, mental health support, and prosthetics to war-affected amputees. The UKRHelp Foundation also works to provide training and education to Ukrainian medical technicians on how to care for those with amputations. This includes providing education for maintaining prosthetic devices over time.

For over three decades, Cornerstone Prosthetic & Orthotics has provided Washington State residents with prosthetic and orthotic care. Cornerstone is dedicated to providing its patients with the highest quality prosthesis and orthotic devices possible to achieve their vocational, recreational, and lifestyle goals. They have an in-house fabrication department staffed by ABC Registered technicians who undergo regular continuing education to ensure they produce the most advanced prosthetic technology for their patients. An in-house fabrication department allows them to develop devices to the highest quality standards.

The UKRHelp Foundation and Cornerstone Prosthetic & Orthotics have joined forces to provide medical care, prosthetic limbs, and training for those with amputations in Ukraine. The partnership will bring patients from Ukraine to Washington State to receive rapid prosthetic devices with a quick turnaround time. With the help of this partnership, technician(s) from Ukraine will be sent to Washington State to learn how to maintain the prosthetic and provide long-term care for amputees in Ukraine.

Mike Smith, Partner, and Practioner of Cornerstone Prosthetic & Orthotics, explains, “we are looking forward to continuing our collaboration with UKRHelp Foundation on a meaningful and humanitarian mission to help amputees have access to prosthetic care. Our clinics provide treatment for people of all ages, from the youngest children to seniors. As a veteran myself, being able to care for young adults who have undergone amputation due to warfare carries tremendous significance. We recognize and respect the considerable time and attention of UKR Help, Alex, and his team, to coordinate patients’ journeys from Ukraine. Our hope is that we’ll be able to develop a longstanding relationship to continue to provide essential prosthetic support for amputees.”

With the first patients scheduled to arrive in the first quarter of 2023, the UKRHelp Foundation and Cornerstone Prosthetic & Orthotics look forward to continuing this mission to provide further aid and care to those in need in Ukraine. To learn more about UKRHelp Foundation and how to support this cause, visit https://ukrhelp.us/. To learn more about Cornerstone Prosthetics and Orthotics, visit https://www.cornerstonepo.com/.

Share article on social media or email:

Sunshine Dentistry, Award-Winning Dental Practice, Offering Non-Invasive Sleep Apnea Treatment for Children and Adults


Sunshine Dentistry

Sunshine Dentistry

I’m proud that Sunshine Dentistry offers the most advanced and effective oral appliances and devices to treat sleep apnea and sleep-disordered breathing.

Sunshine Dentistry, recipient of the 2022 Best of Jersey Shore award for Dentistry, Pediatric Dentistry, and Cosmetic Dentistry, is now offering advanced oral appliances and oral devices for children and adults to treat obstructive sleep apnea and sleep-disordered breathing.

According to Sunshine Dentistry Founder, Dr. Eric V. Thomas, Diplomat of the American Sleep and Breathing Academy and the American Academy of Dental Sleep Medicine (AADSM), the risks of disrupted breathing while sleeping are now highly treatable without the need for masks or machines.

“I have spent many years researching the most effective, but minimally invasive treatments that ensure uninterrupted breathing while sleeping. I’m proud that Sunshine Dentistry offers the most advanced and effective oral appliances and devices to treat sleep apnea and sleep-disordered breathing,” he said.

Sunshine Dentistry offers the Vivos® system which is a new approach to the treatment of sleep apnea, as it expands the space inside the mouth to prevent a narrow airway. “Obstructive sleep apnea results from relaxing muscles in the throat while sleeping. When these muscles relax, it narrows the airway. The Vivos device is unique because it treats the underlying cause of sleep apnea, which is an underdeveloped jaw, resulting in a narrow airway. The Vivos device works by gradually expanding the roof of the mouth while adjusting the lower jaw slightly forward. It is a remarkable system,” he said.

The all-age dental practice also offers the ProSomnus oral device, which is worn while sleeping. The ProSomnus oral appliance is a comfortable treatment, resembling a night guard, that fits over the top and lower arch of teeth. It positions the lower jaw in a slightly forward position to prevent obstruction in the airway.

“Sleep apnea and sleep-disordered breathing in children result in a failure to thrive, delayed development, and problems with concentration and attention. As we age, these conditions contribute to an increased risk of heart disease, and chronic illnesses including diabetes. Fortunately, these highly advanced, minimally invasive devices reduce those risks,” Dr. Thomas said. Both treatments also reduce teeth grinding, and can mitigate pain in the jaw caused by a TMJ disorder.

“Preventative care is essential for good oral health and good overall health. We now understand just how vital it is to ensure that patients of all ages are getting sufficient, uninterrupted sleep. It is clear that treating sleep apnea and sleep disorders in children is necessary to maintain good long-term health. I’m thrilled that our practice gets to play a role in that process,” Dr. Thomas said.

Sunshine Dentistry provides complete oral health care and dental care to patients of all ages. In addition to treatment for obstructive sleep apnea, and sleep-disordered breathing in children, the practice offers complete restorative care and cosmetic treatments.

About Sunshine Dentistry

Sunshine Dentistry is an award-winning all-age dental practice. In addition to Founder Dr. Eric Thomas, Dr. Aleesha Kapoor and Dr. Tyler Kane also provide pediatric, cosmetic, and restorative dental care at Sunshine Dentistry. Sunshine Dentistry is located at 209 South Main Street, Cape May Court House, NJ 08210. To learn more visit https://www.mysunshinedentistry.com or call 609-465-5415.

Share article on social media or email:

Scientist.com Awards $50,000 to Collegiate STEM Research Stars


News Image

“We wanted to recognize undergrad scientists for their contribution to research grant revenue, which often far surpasses the funding generated by collegiate athletic programs.” — Dan Kagan, PhD, President and COO at Scientist.com

Scientist.com, the biopharma industry’s leading R&D marketplace, today announced that 10 undergraduate STEM (Science, Technology, Engineering and Math) students have been chosen as recipients of the inaugural Scientist.com STEM Research NIL Award. The award enables STEM undergrads conducting research within an academic laboratory to be compensated for their work much like collegiate athletes are now compensated under the NCAA’s 2019 NIL rule. The grant winners were selected from over 100 applicants, comprising students from 60 universities. Each of the award recipients are college juniors or seniors who have secured a laboratory research position for 2023.

“We wanted to recognize undergrad scientists for their contribution to research grant revenue, which often far surpasses the funding generated by collegiate athletic programs,” stated Dan Kagan, PhD, President and COO at Scientist.com. “To highlight the discrepancy, we chose to provide this award as a NIL grant instead of a traditional scholarship. We believe student researchers should be treated as equals to student athletes.”

Twenty major US universities generated over $1 billion in 2022 in research grant revenue, including University of California, Los Angeles (UCLA) and University of California, San Diego (UCSD), who both drew in around $1.4B.

For a full list of recipients of the Scientist STEM Research NIL Award, visit https://www.info.scientist.com/nil-award-winners

To learn more about the program, visit https://www.info.scientist.com/scholarships

About Scientist.com

Scientist.com’s mission is to empower and connect scientists worldwide. The company’s digital research platform combines a custom-built, cloud native technology stack with white-glove customer and scientific support to enable scientists to run more innovative experiments in less time and at lower cost. Scientist.com leverages internally developed machine learning models to provide actionable insights that improve operational efficiency and effective research management. Scientist.com connects the world’s top pharmaceutical companies, biotechnology companies and the US National Institutes of Health (NIH) to the world’s largest network of scientific suppliers.

Join Scientist.com on social media: YouTube, LinkedIn, Twitter, Facebook and Instagram.

Share article on social media or email:



RARE-X to Launch an Open Science Data Challenge to Address Rare Neurodevelopmental Diseases


News Image

“This challenge should demonstrate to researchers, drug developers, and patient advocates that people today are already using our data platform to unleash a new understanding of rare diseases to drive improvements in the diagnosis and treatments,” said Charlene Son Rigby, CEO of Global Genes.

RARE-X, the Global Genes collaborative platform for rare disease patients to share their data to accelerate the development of diagnoses and treatments, today announced its inaugural Xcelerate RARE: An Open Science Data Challenge to bring together researchers and data scientists to use patient-provided data to address unanswered research questions about rare diseases.

The open science data challenge is intended to generate new insights into these conditions and allow participants to test hypotheses to fuel therapeutic development by leveraging the expanding amount of patient data on the RARE-X platform and federated data sets. The event will be built around three challenge questions intended to attract different researchers and scientists. RARE-X is working with Dream Challenge through the nonprofit Sage Bionetworks to craft the challenge questions and create a dedicated analysis workspace.

“RARE-X, until recently, has focused on building out its platform and working with rare disease patient advocates to collect and share data,” said Charlene Son Rigby, CEO of Global Genes. “This open science data challenge should demonstrate to researchers, drug developers, and patient advocates that people today are already using our data platform to unleash a new understanding of rare diseases to drive improvements in the diagnosis and treatments of these conditions.”

More than 25 rare disease communities represented by over 40 patient advocacy groups are participating in the challenge. Patients and their families affected by these conditions are actively entering their health data onto the RARE-X data platform to enable researchers to make discoveries.

The challenge questions will include one aimed at identifying previously unrecognized symptoms, a second focused on creating machine learning algorithms to predict disease diagnoses based on the diagnostic journey that is documented by these families contributing and sharing data, and a third one aimed at using data to further a therapeutic hypothesis. The RTW Charitable Foundation, one of the Xcelerate RARE sponsors, has set aside grant funding for up to three submissions that provide a compelling therapeutic hypothesis to test in a lab.

“The Open Science Data Challenge is like a long-form hackathon,” said Karmen Trzupek, Senior Director of Scientific Programs for Global Genes. “With the Open Science Data Challenge, we’re bringing together people who wouldn’t normally see, use, and work on this data into the rare disease space to encourage deep thought, collaboration, and communication to vet research ideas and develop them, not over a weekend, but over two months. The longer timeframe enables more people to participate.”

There are many ways for people to get involved in Xcelerate RARE. Families battling rare pediatric neurodevelopmental diseases can complete surveys on the RARE-X platform, including patient-reported symptoms and validated patient-reported outcome measures (PROMs). Participants who have genetic test reports should upload them to the RARE-X platform for expert curation by the RARE-X team.

Academic researchers, data scientists, and their research teams are encouraged to join the open science data challenge to work on important problems facing rare disease families and compete for grants and prizes. It’s also an opportunity for researchers working for biopharmaceutical companies to get access to rare disease patient data in a pre-competitive, open environment. This data can help their team better understand the underlying biological mechanisms of neurodevelopmental diseases to develop insights into potential therapeutic approaches and advance their research pipeline.

RARE-X is seeking judges with clinical expertise in neurodevelopmental diseases, rare disease research, and machine learning models of predictive diagnosis. The organization also welcomes sponsors who can provide prizes or external data for harmonization efforts. In addition to RTW Charitable Foundation, RARE-X will also be partnering with Roche, the Alliance for Artificial Intelligence in Healthcare, and NetraMark, plus receiving expert advice from the U.S. Food and Drug Administration to deliver Xcelerate RARE.

“Ultimately, our goal is to advance rare disease understanding and meaningful therapeutic research for rare diseases,” said RARE-X’s Trzupek. “For this inaugural event, we have reasonable expectations. We don’t necessarily expect the patient-reported data we’ve collected in just over a year to generate a blockbuster therapeutic idea overnight, but we firmly believe that patient-reported data is powerful and can be used to fuel and to test therapeutic hypotheses.”

For more information on Xcelerate RARE visit the RARE-X website.

Or listen to the RARE-Xtra Podcast on An Open Science Data Challenge to Address Rare Neurodevelopment Diseases.

About Global Genes

Global Genes is a 501(c)(3) nonprofit organization dedicated to eliminating the burdens and challenges of rare diseases for patients and families globally. In pursuit of that mission, Global Genes connects, empowers, and inspires the rare disease community to stand up, stand out, and become more effective on their own behalf ⁠— helping to spur innovation, meet essential needs, build capacity and knowledge, and drive progress within and across rare diseases. Global Genes serves more than 400 million people around the globe, and nearly one in 10 Americans affected by rare diseases. If you or someone you love has a rare disease or are searching for a diagnosis, contact Global Genes at 949-248-RARE or visit the Resource Hub.

About RARE-X

RARE-X is a program of Global Genes focused on supporting the acceleration and development of life-altering treatments and future cures for patients impacted by a rare disease. Enabled by best-in-class technology, patients, researchers, and other technology vendors, RARE-X gathers structured, fit-for-purpose data to share broadly, benefitting from 21st-century governance, consent, and federated data-sharing technology. Through RARE-X, Global Genes is building the largest collaborative patient-driven, open-data access project for rare diseases globally. For more information, visit http://www.rare-x.org.

Media Contact:

Tom Hume

Marketing Communications

Global Genes/RARE-X

tom.hume@globalgenes.org

Share article on social media or email: